SCHEMBL4852707

SCHEMBL4852707

CCOC(=O)COc1c(C)cc(N(Cc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)C(=O)OC(C)(C)C)cc1C

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.47
PPARA Q07869 15/20 0.46
PPARG P37231 12/20 0.46
FFAR1 O14842 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854322 0.89 FFAR1 (0.51) PPARDPPARAPPARGFFAR1
SCHEMBL4861431 0.86 PPARD (0.50) PPARDPPARAPPARGFFAR1
SCHEMBL27650490 0.86 PPARD (0.53) PPARDPPARAPPARGFFAR1
SCHEMBL4854448 0.83 PPARD (0.55) PPARDPPARAPPARGFFAR1
SCHEMBL4856754 0.82 PPARD (0.45) PPARDPPARAPPARGFFAR1
SCHEMBL27630341 0.80 PPARD (0.53) PPARDPPARAPPARGFFAR1
SCHEMBL4853525 0.79 FFAR1 (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL4853039 0.79 PPARD (0.62) PPARDPPARAPPARGFFAR1
SCHEMBL4860779 0.77 PPARD (0.59) PPARDPPARAPPARGFFAR1
SCHEMBL4854263 0.76 PPARD (0.65) PPARDPPARAPPARGFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG PPARD 2/4885PPARA 1/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.